Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
PHASE3
A global study to evaluate peri-operative pembrolizumab with chemotherapy v...
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
PHASE2
The purpose of this study is to test if immunotherapy with nivolumab alone ...
Status
Active Not Recruiting
Location
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
PHASE3
This is a study of perioperative pembrolizumab or enfortumab vedotin in com...
Status
Active Not Recruiting
Location
University of South Alabama, Mitchell Cancer Institute ( Site 1582)